Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine Conversion for New Onset Diabetes in Liver Transplant
NCT00171717Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2004
- Primary completion
- Dec 2005
- Modality
- Peptides, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine in Liver transplant rejection, sponsored by Novartis. Primary endpoint: Percentage of patients whose diabetes resolves 6 months after the conversion. Started Feb 2004; status: completed.
02
Drugs
cyclosporine
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00171717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171717.